Morgan Stanley Maintains Equal-Weight on Sigilon Therapeutics, Raises Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison maintains an Equal-Weight rating on Sigilon Therapeutics (NASDAQ:SGTX) and raises the price target from $7 to $21.
July 03, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley maintains an Equal-Weight rating on Sigilon Therapeutics and raises the price target from $7 to $21.
The news is directly related to Sigilon Therapeutics. The increase in price target from $7 to $21 by Morgan Stanley indicates a positive outlook for the company's stock in the short term. This could potentially lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100